Abstract: A resin including up to 99.99 weight percent (wt. %) of a first polyolefin grafted with a functional group selected from an ethylenically unsaturated carboxylic acid, a carboxylic acid anhydride, an ester functional group or a combination thereof; and 0.01 to 3.0 wt. % of a tin oxide-based catalyst, where the resin includes 0.2 wt. % to 1.5 wt. % of the functional group from the first polyolefin, the wt. % based on a total weight of the resin. The first polyolefin can be selected from a polyethylene, a polypropylene, an ethylene/alpha-olefin copolymer, a propylene/alpha-olefin copolymer and combinations thereof. The tin oxide-based catalyst can be selected from dibutyltin oxide, dioctyltin oxide and combinations thereof. The resin can be used in a multilayer structure, where a Layer A comprises the resin and a Layer B comprises a polyester, where a first major surface of Layer A is in adhering contact with the second major surface of Layer B.

Abstract: CD19 variants, methods of identifying CD19 variants, and methods of using such CD19 variants, e.g., for treating cancer, are described.

Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.

Abstract: Methods and recombinant vectors for increasing resistance to Fusarium head blight (FHB) infection in plants. Exogenous Fhb1 nucleic acids are described to generate transgenic plants having increased resistance to FHB relative to a control plant. The nucleotide sequence of the exogenous nucleic acid comprises SEQ ID NO:1, 2, 4, 5, or 6; has at least 95% sequence identity to SEQ ID NO:1, 2, 4, 5, or 6; encodes a protein comprising the amino acid sequence of SEQ ID NO: 3, 7, 8, or 9; or encodes a protein having at least 95% amino acid identity to SEQ ID NO: 3, 7, 8, or 9.

Abstract: A device includes a balloon and an interface. The balloon has an outer surface and a central lumen aligned on a longitudinal axis. The balloon is configured to receive a compressible fluid. The interface is coupled to the outer surface and has an external surface configured to bond with a tissue.

Abstract: The present invention relates to methods for providing lysosomal enzymes to a subject by administering stem cells, preferably Multipotent Adult Progenitor Cells (MAPCs). The invention further relates to methods for treating lysosomal storage disorders by administering stem cells.

Abstract: The invention provides compounds of formula I, II, III, or IV: wherein R1 to R11, X, and Y have any of the values defined in the specification. The compounds inhibit Na, K-ATPase ?4 and are useful as contraceptive agents.

Abstract: The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, endodermal, and mesodermal embryonic germ layers, e.g., stem cells.

Abstract: Ad40-based polynucleotides, viral vectors, methods of making such polynucleotides and viral vectors, pharmaceutical compositions that includes such polynucleotides and viral vectors, and uses of such compositions are disclosed herein. Generally, the Ad40-based polynucleotide includes an Ad40-based vector that includes a genetic modification that decreases expression of an E1 coding region and a heterologous polynucleotide.

Abstract: This disclosure describes engineered biosynthetic pathways, recombinant cells, and methods relating to biosynthesis of esters. The recombinant cells may be modified to exhibit increased biosynthesis of an ester compared to a wild-type control. The recombinant cell may be incubated in medium that includes a carbon source under conditions effective for the recombinant cell to produce an ester. This disclosure also describes a method that generally includes introducing into a host cell a heterologous polynucleotide encoding at least one polypeptide that catalyzes a step in converting a carbon source to an ester, wherein the at least one polynucleotide is operably linked to a promoter so that the modified host cell catalyzes conversion of the carbon source to an ester.

Abstract: Provided herein are polynucleotides that bind to fractalkine. In one embodiment, a polynucleotide includes the polynucleotide sequence SEQ ID NO:1 or a sequence having at least 80% identity to SEQ ID NO:1. Also provided herein are structures that include such a polynucleotide present on its surface, including 2-dimentional and 3-dimentional structures. Also provided are compositions that include such a polynucleotide, and methods for using the polynucleotides.

Abstract: The invention provides a compound of formula (I) or a salt thereof, as well as compositions comprising such compounds. The compounds and compositions are useful as analgesics.

Abstract: The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF.

Abstract: The invention provides compounds of Formula (I) and (IV): as described herein, as well as salts thereof. The compounds have anti-cancer properties and/or chemosensitization properties.

Abstract: A method is proposed for characterizing a totality of particles. The method can be used in particular for characterizing microparticular or nanoparticular aerosols. The method comprises the following steps: a) in a classification step, a class of the totality is selected, wherein the particles of the selected class have a prespecified mobility dm; b) in a counting step, a number N of the particles of the selected class is determined; c) in a charge determination step, a charge Q of the particles of the selected class is determined; and d) in an evaluation step, at least one morphological parameter is determined from the charge Q, the number N and the mobility dm, wherein the morphological parameter comprises at least one item of information about an agglomerate state of the particles.

Abstract: An AC machine control system for an AC machine (motor, generator, transformer, etc.) having open-ended windings, the control system comprising a drive circuit configured to transfer AC power between a first set of voltages and each end of the open-ended windings without the use of a substantial energy storage device, while eliminating common mode voltage and/or injecting zero sequence voltages.

Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.

Abstract: A fluid treatment device and method are provided for generating an electric field across a gap between first and second electrode and for concentrating the electric field within a fluid treatment chamber located in the gap.

Abstract: A calcium lactate crystal inhibitor is added to the typical cheese-making recipe to inhibit the growth of calcium lactate crystals as the cheese ages. The calcium lactate crystal inhibitor is preferably a sodium salt of an organic acid, and is preferably added with sodium chloride or shortly after sodium chloride as part of the salting step. The calcium lactate crystal inhibitor can be identified in a solubility model as being effective in preventing calcium lactate crystal formation by having no or essentially no visually observable crystals and a minimal reduction (less than 5.0%, and more preferably less than 1.0%) in the calcium and lactate content of a calcium L-lactate pentahydrate solubility solution after 14 days of storage at 7° C. The amount of calcium lactate crystal inhibitor salt is within the range of greater than zero to 10% of the weight of the curd, to result in a cheese having 0.26 to 2.8% calcium lactate crystal inhibitor in a cheddar cheese.

Abstract: The invention provides for antisense oligonucleotides that hybridize to casein kinase 2 nucleic acid sequences and methods of using such antisense oligonucleotides to inhibit expression of casein kinase 2 and reduce the size of solid tumors.